P119 Design of a randomized, open-label trial adding custirsen, a novel clusterin inhibitor, to cabazitaxel/prednisone in second-line treatment of metastatic Castration-Resistant Prostate Cancer (mCRPC): The AFFINITY phase 3 study

✍ Scribed by Beer, T.M.; Blumenstein, B.A.; Fizazi, K.; Hotte, S.J.; Jacobs, C.; Stewart, P.S.

• Book ID: 122278865
• Publisher: Elsevier Science
• Year: 2013
• Tongue: English
• Weight: 65 KB
• Volume: 12
• Category: Article
• ISSN: 1569-9056
• DOI: 10.1016/S1569-9056(13)62443-4